Addition Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-12-22.
Addition Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 22, 2025. The filing reports $28M sold. Its industry group is Biotechnology. It names Ronald Park (Executive Officer, Director), Peter Bisgaard (Director), Kathleen Collins (Director) (SEC Form D, December 22, 2025).
Sell to companies like Addition Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-22 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Addition Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Addition Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in December 2025, largest first.
Get an email when Addition Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Addition Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Addition Therapeutics, Inc. →Get the full cited report on Addition Therapeutics, Inc.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Addition Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Addition Therapeutics, Inc. See pricing
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $28M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Ronald Park is named as Executive Officer and Director on the Form D that Addition Therapeutics, Inc. filed with the SEC on 22 December 2025, one of 8 people that filing names.
Peter Bisgaard is named as Director on the Form D that Addition Therapeutics, Inc. filed with the SEC on 22 December 2025, one of 8 people that filing names.
Kathleen Collins is named as Director on the Form D that Addition Therapeutics, Inc. filed with the SEC on 22 December 2025, one of 8 people that filing names.
Matthew Patterson is named as Director on the Form D that Addition Therapeutics, Inc. filed with the SEC on 22 December 2025, one of 8 people that filing names.
Laetitia Schwab is named as Director on the Form D that Addition Therapeutics, Inc. filed with the SEC on 22 December 2025, one of 8 people that filing names.
Jennifer Lee is named as Director on the Form D that Addition Therapeutics, Inc. filed with the SEC on 22 December 2025, one of 8 people that filing names.
Jayson Punwani is named as Director on the Form D that Addition Therapeutics, Inc. filed with the SEC on 22 December 2025, one of 8 people that filing names.
Lawrence Kong is named as Executive Officer on the Form D that Addition Therapeutics, Inc. filed with the SEC on 22 December 2025, one of 8 people that filing names.
8 people named on the filing — 2 holding an executive role and 6 as directors only.
Named as of the 2025-12-22 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Addition Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Addition Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Addition Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Addition Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Addition Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Francisco Bay Area
https://mentionfox.com/funding/addition-therapeutics-inc-form-d-25000001